Critique of ‘Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial’ ☆☆Critique of: Richard P. Dutton, Michael Parr, Bartholomew J. Tortella et al. Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial, The Journal of TRAUMA Injury, Infection, and Critical Care. Volume 71, Number 1, July 2011

Critique of ‘Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial’ ☆☆Critique of: Richard P. Dutton, Michael Parr, Bartholomew J. Tortella et al. Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial, The Journal of TRAUMA Injury, Infection, and Critical Care. Volume 71, Number 1, July 2011

Background: Safety data on recombinant activated factor VII (rFVIIa, NovoSeven; Novo Nordisk A/S, Bagsværd, Denmark) in actively hemorrhaging trauma patients are limited. We present detailed safety data from a large multicenter, randomized, placebo-controlled phase III study (the CONTROL trial). Met...

Full description

Bibliographic Details
Main Authors: Yassir S. Abdulrahman, Mazin A. Tuma, Husham Abdul Rahman, Ruben Peralta, Rifat Latifi
Format: Article
Language:English
Published: HBKU Press 2012-09-01
Series:Journal of Emergency Medicine, Trauma and Acute Care
Online Access:http://www.qscience.com/doi/pdf/10.5339/jemtac.2012.18

Internet

http://www.qscience.com/doi/pdf/10.5339/jemtac.2012.18

Similar Items